Structure Therapeutics Inc.
GPCR
$56.65
$2.905.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.55M | 57.56M | 56.00M | 51.52M | 49.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00M | -- | -- | -- | -- |
| Total Operating Expenses | 186.81M | 247.61M | 219.66M | 182.52M | 158.23M |
| Operating Income | -186.81M | -247.61M | -219.66M | -182.52M | -158.23M |
| Income Before Tax | -140.69M | -210.20M | -178.49M | -142.94M | -122.22M |
| Income Tax Expenses | 515.00K | 481.00K | 465.00K | 379.00K | 310.00K |
| Earnings from Continuing Operations | -141.20 | -210.69 | -178.95 | -143.32 | -122.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.20M | -210.69M | -178.95M | -143.32M | -122.53M |
| EBIT | -186.81M | -247.61M | -219.66M | -182.52M | -158.23M |
| EBITDA | -185.13M | -246.40M | -218.55M | -181.48M | -157.23M |
| EPS Basic | -7.47 | -10.94 | -9.36 | -7.72 | -6.95 |
| Normalized Basic EPS | -1.53 | -2.14 | -1.81 | -1.47 | -1.31 |
| EPS Diluted | -7.47 | -10.94 | -9.36 | -7.72 | -6.95 |
| Normalized Diluted EPS | -1.53 | -2.14 | -1.81 | -1.47 | -1.31 |
| Average Basic Shares Outstanding | 236.78M | 230.69M | 229.41M | 221.28M | 210.50M |
| Average Diluted Shares Outstanding | 78.93M | 76.90M | 76.47M | 73.76M | 70.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |